An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
Status:
Terminated
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, single arm study to evaluate the efficacy and safety of
APX001 for the treatment of candidemia and/or invasive candidiasis caused by C. auris in
patients aged 18 years and over with limited antifungal treatment options.